Lancet Neurol
Published

Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial.

Authors

Suvankar Pal, Jeremy Chataway, Robert Swingler, Malcolm R Macleod, Neil O Carragher, Giles Hardingham, Bhuvaneish Thangaraj Selvaraj, Colin Smith, Charis Wong, Judith Newton, Dawn Lyle, Amy Stenson, Rachel S Dakin, Amarachi Ihenacho, Shuna Colville, Arpan R Mehta, Nigel Stallard, James R Carpenter, Richard A Parker, Catriona Keerie, Christopher J Weir, Bruce Virgo, Stevie Morris, Nicola Waters, Beverley Gray, Donald MacDonald, Euan MacDonald, Mahesh K B Parmar, Siddharthan Chandran,
Read More

Abstract

Motor neuron disease represents a group of progressive and incurable diseases that are characterised by selective loss of motor neurons, resulting in an urgent need for rapid identification of effective disease-modifying therapies. The MND SMART trial aims to test the safety and efficacy of promising interventions efficiently and definitively against a single contemporaneous placebo control group. We now report results of the stage two interim analysis for memantine and trazodone.

PMID:39307154 | DOI:10.1016/S1474-4422(24)00326-0

UK DRI Authors

Suvankar Pal profile

Prof Suvankar Pal

UK DRI Co-investigator

Professor of Neurodegenerative Disorders and Clinical Trials and Honorary Consultant Neurologist, University of Edinburgh

Prof Suvankar Pal
Giles Hardingham

Prof Giles Hardingham

Centre Director

Studying astrocytes to better understand their role in helping maintain a healthy brain

Prof Giles Hardingham
Colin Smith Profile

Prof Colin Smith

Chair of Neuropathology; Director of Centre for Clinical Brain Sciences

Prof Colin Smith
Siddharthan Chandran

Prof Siddharthan Chandran

Director & CEO

Dissecting a genetic cause of ALS and FTD and identifying ways to help protect neurons

Prof Siddharthan Chandran